BioCentury
ARTICLE | Company News

HistoRx, Yale University deal

January 2, 2012 8:00 AM UTC

The university granted HistoRx rights to an assay that identifies melanoma patients who have a 40% risk of recurrence of the disease despite having no detectable cancer in their lymph nodes. The assay...